Cartilage Oligomeric Matrix Protein (COMP) ELISA Kits

Horse (Equine) Cartilage Oligomeric Matrix Protein (COMP) interaction partners

1. The aims of this study were to investigate the proteomic composition of injured tendons during early and late disease stages to identify disease-specific cleavage patterns of the extracellular matrix protein cartilage oligomeric matrix protein (COMP).

2. The present results suggest that not only type III collagen (show COL3A1 ELISA Kits) but also cartilage oligomeric matrix protein is involved in the repair and remodeling processes of the digital flexor tendon.

3. Within the limitations of the study design, production of COMP during healing of skin wounds does not appear to be influenced by wound type or anatomic site, nor does it appear to be correlated with TGF-beta1 (show TGFB1 ELISA Kits) concentrations.

4. COMP concentrations in digital flexor tendon sheath synovial fluid were significantly greater than those in normal horses with noninfected tenosynovitis caused by intrathecal tendon/ligament tearing, but not by other lesions.

5. The present study indicates that dynamic in vivo compression at high load and frequency lowers matrix content of COMP in the articular cartilage of the third carpal bone.

Human Cartilage Oligomeric Matrix Protein (COMP) interaction partners

1. These findings suggest that Zalpha domain of human ADAR1 (show ADAR ELISA Kits) binding with the GAC (show GLS ELISA Kits) hairpin stem in COMP can lead to a non-genetic, RNA editing-mediated substitution in COMP that may then play a crucial role in the development of pseudoachondroplasia.

2. Higher serum COMP levels in knee osteoarthritis reflect knee structural damage.

3. COMP (and C-reactive protein (show CRP ELISA Kits)) serum levels were both associated with the incidence of knee osteoarthritis.

4. Data indicate cartilage oligomeric matrix protein (COMP) homozygote missense variant [c.1423G>A; p.(D475N)] in 2 severely affected pseudoachondroplasia individuals.

5. The serum COMP is a promising biomarker in rheumatoid arthritis which reflects disease activity and damage to the articular cartilage.

6. the novel mutation of COMP may result in intracellular accumulation of the mutant protein. Decreased plasma COMP and increased plasma CTX (show CYP27A1 ELISA Kits)-II may potentially serve as diagnostic markers of PSACH but may not be applicable in the presymptomatic carrier.

7. COMP promoted colon cancer cell proliferation partially through the activation of PI3K (show PIK3CA ELISA Kits)/ Akt (show AKT1 ELISA Kits)/ mTOR (show FRAP1 ELISA Kits)/ p70S6K (show RPS6KB1 ELISA Kits) pathway.

8. The findings suggest that upregulation of ADAMTS-7 (show ADAMTS7 ELISA Kits) and down regulation of COMP are associated with human AA.

9. Data show that a rare missense variant in the COMP gene (cartilage oligomeric matrix protein) and a frameshift variant in the CHADL gene (chondroadherin-like protein) strongly associate with osteoarthritis total hip replacement.

10. COMP is a novel biomarker in breast cancer, which contributes to the severity of the disease by metabolic switching and increasing invasiveness and tumor cell viability, leading to reduced survival in animal models and human patients.

Mouse (Murine) Cartilage Oligomeric Matrix Protein (COMP) interaction partners

1. COMP could normally have a protective role against PASMC phenotype switching

2. these findings revealed the essential role of COMP in retarding the development of vascular aging and vascular smooth muscle cell senescence.

3. COMP deficiency drove macrophages toward the atherogenic phenotype and thereby aggravated atherosclerotic calcification.

4. COMP forms a complex with collagens intracellularly that is a prerequisite for collagen secretion.

5. COMP-Ang1 (show ANGPT1 ELISA Kits) can enhance BMP2 (show BMP2 ELISA Kits)-induced cranial bone regeneration with increased pericyte recruitment. Combined delivery of the proteins might be a therapeutic strategy to repair cranial bone damage.

6. COMP deficiency shortened tail-bleeding and clotting time and accelerated ferric-chloride-induced thrombosis. COMP specifically inhibited thrombin-induced platelet aggregation, activation, and retraction and the thrombin-mediated cleavage of fibrinogen.

7. COMP immunoreactivity was observed in about half of the investigated plaques from the ApoE (show APOE ELISA Kits) null mice, mainly located along the intima-medial border. Plaques in the brachiocephalic artery from ApoE (show APOE ELISA Kits) mice lacking COMP were increased in size with 54%.

8. study will facilitate better awareness of the differential diagnoses that might be associated with the PSACH/MED spectrum and subsequent care of PSACH/MED patients

9. The lack of arthritis, together with high levels of COMP-specific antibodies, in COMP-deficient mice indicates that susceptibility to arthritis is COMP specific and that endogenous expression of COMP in wild-type mice tolerizes B cells in vivo.

10. results imply that COMP is not a key upstream mediator of the anabolic effects of ML on the skeleton.

Cow (Bovine) Cartilage Oligomeric Matrix Protein (COMP) interaction partners

1. COMP synthesis is differentially regulated by TGFbeta1 (show TGFB1 ELISA Kits) in the surface and middle zones of bovine articular cartilage.

2. role for proteinases other than MMPs in the degradation of COMP in cartilage

3. COMP mutant expression in tendon fibroblasts leads to increased apoptotic cell death irrespective of the secretory characteristics of mutant COMP

4. COMP mRNA expression level was markedly increased by ball oscillation.

5. COMP acts as a catalyst in collagen fibrillogenesis.